Influence of SGLT2 inhibitor-assisted levosimendan on cardiac function and prognosis in patients with acute heart failure
Objective:To explore the influence of sodium-dependent glucose transporter 2(SGLT2)inhibitor-assisted levosimendan on cardiac function and prognosis in patients with acute heart failure(AHF).Methods:A total of 69 patients in the hospital from January 2022 to December 2023 were included and divided into the conventional group(n=34,conventional anti-heart failure treatment combined with levosimendan)and the SGLT2 group(n=35,SGLT2 inhibitor based on conventional group)according to simple randomization(random number table method).The clinical efficacy was compared.Before and after 6 months of treatment,left atrial volume index(LAVI)and left ventricular mass index(LVMI)were monitored using an electrocardiogram,and central venous pressure(CVP)and cardiac output(CO)were measured using a hemodynamic analyzer.Adverse drug reactions and readmission rates were also statistically analyzed.Results:The overall efficacy of the SGLT2 group was significantly higher than that of the conventional group(P<0.05).After 6 months of treatment,both groups showed significant decreases in LAVI,LVMI,and CVP(P<0.05),and the SGLT2 group was significantly lower than the conventional group(P<0.05).After 6 months of treatment,both groups showed significant increases in CO(P<0.05),and the SGLT2 group was significantly higher than the conventional group(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).The readmission rate(0.00%)of the SGLT2 group was significantly lower than that of the conventional group(11.76%)(P<0.05).Conclusion:SGLT2 inhibitors assisted with levosimendan can effectively treat AHF,strengthen left ventricular function,improve hemodynamics,have minimal adverse drug reactions,have high safety,and have a positive impact on prognosis,and are worthy of promotion and application.
NETL
NSTL
万方数据
